

REMARKS

Responsive to the Restriction Requirement mailed August 27, 2007, Applicant hereby elects **Invention I** (Claims 100,102, 194-200, 203, 210-213, 217-228 and 412, drawn to a formulation for therapeutic or diagnostic use comprising targeted gas-filled vesicles which comprise one or more membranes, wherein each of said membrane is in solid state, each of said membranes defining an internal void that contains a substantially insoluble substance, the substance being in gaseous form at ambient conditions, the substance selected from the group consisting of perfluorocarbons and sulfur hexafluoride, said solid state membrane comprising a phospholipid, and being free of disulfide linkages, and further comprising a lipid covalently conjugated to a targeting ligand via a linking group, where in said linking group is a hydrophilic polymer selected from the group consisting of polyethylene glycol (PEG), polypropylene glycol, polyvinylalcohol, polyvinylpyrrolidone, and copolymers thereof, and wherein said targeting ligand is selected from the group consisting of proteins, peptides, saccharides, steroids, steroid analogs, bioactive agents and genetic material) without traverse.


In re Application of:
Unger et al.
Application No.: 09/218,660
Filed: December 22, 1998
Page 3 of 3

PATENT
Attorney Docket No. IMARX1100-3

The Commissioner is hereby authorized to charge \$525.00 as payment for the Petition for Three-Month Extension of Time fee to Deposit Account No. 07-1896. Additionally, the Commissioner is hereby authorized to charge any other fees that may be due in connection with the filing of this paper, or credit any overpayment to Deposit Account No. 07-1896, referencing the above-identified attorney docket number.

Respectfully submitted,

Date: December 27, 2007



Victor Repkin
Attorney for Applicants
Reg. No. 45,039
Telephone: (858) 638-6664
Facsimile: (858) 677-1465

DLA PIPER US LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133
USPTO CUSTOMER NUMBER: 28213